Published: 2009-09-03 09:07:34 CEST
Diamyd Medical AB - Company Announcement
4 year follow-up of Diamyd® Phase II study shows clear positive trend
Diamyd Medical announced today that the company's 4-year follow-up of type 1    
diabetes patients included in the company's Phase II study shows a clear        
positive trend.                                                                 

Diamyd Medical received approval from the Swedish Medical Products Agency in    
February to follow up the children and adolescents with type 1 diabetes that    
were included in the company's previously reported Phase II study with the      
diabetes vaccine Diamyd®. The participants were treated with 2 injections of    
Diamyd® or placebo; one injection at the study start in 2005 and one injection  
one month later. Initial analysis of new data shows, that patients treated with 
the Diamyd®  vaccine early after diagnosis have a clearly better diabetes status
compared to the corresponding placebo group, still 4 years after the injections.
Also safety data continue to look good without any serious side effects related 
to the treatment. The patients will additionally be followed regarding Quality  
of Life and diabetes complications. The study period is 7 years. All            
participants in the study were offered to participate in the follow-up and      
approximately two thirds have accepted.                                         

“This is extremely promising,” says Elisabeth Lindner, CEO and President of     
Diamyd Medical. “We have already shown that the vaccine has managed to          
significantly change the course of diabetes in Diamyd® -treated patients. The   
fact that two single injections still seem to have an effect 4 years later is to
be regarded as very good news.”                                                 

Diamyd Medical is conducting a global Phase III program for the Diamyd® diabetes
vaccine, which includes a total of 640 children and adolescents newly diagnosed 
with type 1 diabetes. The program comprises one study involving nine European   
countries and one parallel study in the US. The purpose of the Phase III studies
is to confirm and evaluate the ability of the Diamyd® vaccine to halt or slow   
the autoimmune destruction of the body's insulin-producing cells, thereby       
preserving the body's own ability to produce insulin in people with type 1      
diabetes.                                                                       

For additional information, please contact:                                     
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.)                  
Tel: +46 (0)8 661 0026                                                          

For pictures and press material, please contact:                                
Andreas Ericsson, Diamyd Medical AB (publ.)                                     
andreas.ericsson@diamyd.com                                                     
Tel:+46 (0)8 661 0026  
                                                         
About Diamyd Medical                                                            
Diamyd Medical is a Swedish diabetes company focusing on                        
the development of pharmaceuticals for the treatment of autoimmune diabetes and 
its complications. The company's most advanced project is the GAD-based drug    
Diamyd® for type 1 diabetes. Phase III trials for this drug are in progress in  
both Europe and the US. In addition, the company has initiated clinical studies 
in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery  
System (NTDDS). The company has also out-licensed the use of GAD for the        
treatment of Parkinson's disease. The company currently has three clinical-phase
products.                                                                       

Diamyd Medical has offices in Sweden and in the US. Shares are listed on Nasdaq 
OMX in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY)        
administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).     
Further information is available on the company's website: www.diamyd.com.      
This information is disclosed in accordance with the Swedish Securities         
Markets Act, the Swedish Financial Instruments Trading Act, or the requirements 
stated in the listing agreements. 
                                              
Diamyd Medical AB (publ.)                                                  
Linnégatan 89 B,                                                                
SE-115 23 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax: +46 (0)8 661 63 68     
E-mail: info@diamyd.com. VAT no: SE556530-142001.                               
(www.omxnordicexchange.com                                                      
ticker: DIAM B; www.otcqx.com ticker: DMYDY)


pr_eng_4year-090903.pdf